Tcell receptor therapies (TCRTs) and chimeric antigen receptor T cell therapies (CARTs) are created by engineering T cells. TCRTs are engineered to express a Tcell receptor that can recognise both extracellular and intracellular targets, including tumourspecific mutations expressed by cancer cells. CARTs are genetically modified to express a chimeric antigen receptor that recognises a specific, cancerassociated protein on the surface of tumour cells.

We are advancing our diverse pipeline of innovative preclinical and clinical stage CARTs and TCRTs across hardtotreat tumours and malignancies.

Learn more about our ambition in cell therapy: https://www.astrazeneca.com/rd/next...


Global site: https://www.astrazeneca.com/
Careers site: https://careers.astrazeneca.com/

Follow us:
Twitter:   / astrazeneca  
LinkedIn:   / astrazeneca  
Instagram:   / astrazeneca  
Facebook:   / astrazeneca